Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › abatacept

abatacept

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of abatacept

59 trials tracked of abatacept: 32 in phase 3 or 4 and 11 with published results. The most-cited published study has 215 citations.

59Trials tracked
32Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 5 Phase 3 27 Phase 2 23 Phase 1 3 Other / NA 1
  1. Phase 3 Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis Completed · 215 cited
  2. Phase 3 Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) Completed · 180 cited
  3. Phase 3 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Completed · 88 cited
  4. Phase 3 Immune Modulators for Treating COVID-19 Completed · 67 cited
  5. Phase 4 Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis Completed · 51 cited
  6. Phase 3 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs Completed · 51 cited
Show 44 more trials
  1. Phase 4 Abatacept in Juvenile Dermatomyositis Completed · 28 cited
  2. Phase 3 Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Completed · 19 cited
  3. Phase 3 Effects of Abatacept in Patients With Early Rheumatoid Arthritis Completed · 14 cited
  4. Phase 3 Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan Completed · 12 cited
  5. Phase 4 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Completed · 5 cited
  6. Phase 4 Rheumatoid Arthritis Memory B Cells and Abatacept Completed
  7. Phase 4 A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis Completed
  8. Phase 3 Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients Completed
  9. Phase 3 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome Completed
  10. Phase 3 A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Completed
  11. Phase 3 A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Completed
  12. Phase 3 Phase IIIB Subcutaneous Abatacept Monotherapy Study Completed
  13. Phase 3 Abatacept Versus Adalimumab Head-to-Head Completed
  14. Phase 3 A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography Completed
  15. Phase 3 Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis Completed
  16. Phase 3 Phase IIIB Switching From Intravenous to Subcutaneous Study Completed
  17. Phase 3 Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. Completed
  18. Phase 3 A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Completed
  19. Phase 3 Methotrexate-Inadequate Response Autoinjector Device Sub Study Completed
  20. Phase 3 Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis Completed
  21. Phase 3 Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy Completed
  22. Phase 3 A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis Completed
  23. Phase 3 Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis Completed
  24. Phase 3 A Study of Abatacept in Patients With Active Ulcerative Colitis Completed
  25. Phase 3 Phase IIIB Subcutaneous Missed Dose Study Completed
  26. Phase 3 Remission and Joint Damage Progression in Early Rheumatoid Arthritis Completed
  27. Phase 2 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed
  28. Phase 2 Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Completed
  29. Phase 2 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Completed
  30. Phase 2 Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Completed
  31. Phase 2 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches Completed
  32. Phase 2 The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics Completed
  33. Phase 2 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed
  34. Phase 2 A Cooperative Clinical Study of Abatacept in Multiple Sclerosis Completed
  35. Phase 2 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Completed
  36. Phase 2 Safety and Efficacy of Abatacept in IgG4-Related Disease Completed
  37. Phase 2 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed
  38. Phase 2 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Completed
  39. Phase 2 Abatacept as GVHD Prophylaxis Phase 2 Completed
  40. Phase 2 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed
  41. Phase 2 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease Completed
  42. Phase 2 Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Completed
  43. Phase 2 Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients Completed
  44. Phase 2 Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Allergy & Immunology Sys. Review
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Frontiers Jun 4, 2026
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Ophthalmology
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
medRxiv Apr 14, 2026
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis
Rheumatology RCT
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis Early rheumatoid arthritis patients report similar symptom relief with different treatment approaches
This open-label randomized trial in 795 newly diagnosed, DMARD-naïve RA patients compared three biological DMARDs plus methotrexate against …
In early rheumatoid arthritis, patients reported similar pain relief and quality-of-life improvements whether they started with conventional…
Apr 9, 2026
Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA treated with abatacept plus methotrexate or methotrexate alone
Rheumatology RCT
Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA treated with abatacept plus methotrexate or methotrexate alone Early disease activity and response predict remission in ACPA-positive rheumatoid arthritis patients
This post-hoc analysis of randomized controlled trials and an observational cohort evaluated predictors of DAS28-CRP remission in ACPA-posit…
Only early disease activity and treatment response predict remission in ACPA-positive rheumatoid arthritis, while genetic markers and imagin…
Apr 8, 2026
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Nephrology Phase II
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers.
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…
CT.gov Mar 28, 2026